There have been rumors about generic Copaxone (glatiramer acetate) floating around for some time. This is a biggie, as Copaxone has almost 40% of the US MS market.
Here is what is happening right now (from what I can figure out):
Teva, the manufacturer of Copaxone, is trying to stop generic Copaxone from being produced and launched. Copaxone makes up about one-third of the company's profit. They have petitioned the US Food and Drug Administration (FDA) to stop the generics, claiming that any generic should have to be tested in a full clinical trial. That would take at least two years.
To stop generics, Teva filed a "Citizens Petition" with the FDA on December 12, 2010. It appears as thought the FDA has postponed their ruling on this petition (probably until September, according to some experts), although there have been some rumors that the FDA rejected the petition.
In addition, Teva has just launched a trial to test a double dose of Copaxone, which would be given three times a week, instead of every day. I am unsure (and can't figure out by reading the news) what this would mean for their patent.
Meanwhile, a company called Mylan is working the courts to file and defend its application to make generic Copaxone, possibly even before Teva's patent expires. Mylan has been sued by Teva, which is claiming patent infringement.
Teva's Copaxone patent expires in the US in 2014 and in Europe in 2015.
Anyone with any additional information or new developments on this issue, please post in the comment section below.